NEWS

News
Feedback
If you have any comments or suggestions, we can give us a message and we will get back to you as soon as possible

HIV vaccine clinical trial results: volunteer 100% produces antibodies

Date: 2017-10-19
Views: 83

Johnson announced in July 24th the world's first HIV vaccine in human clinical trials, this multicenter, randomized, placebo-controlled, double-blind phase 1/2a clinical trial recruited 393 healthy volunteers, volunteers from the United States, Rwanda, Uganda, South Africa and Thailand. The results showed that the volunteers of HIV vaccine was well tolerated, and produced antibody against HIV 100%.

Johnson is the world's largest scale, diversification of products in medical and health care products and consumer care products company, its financial support is an important reason for this vaccine has achieved remarkable results, the specific test undertaken by Yang Sen pharmaceutical company and its subsidiary, but the technology from the American Medical College of Harvard University and other research institutions.

The HIV vaccine is a mosaic vaccine, namely the use of a variety of antigen HIV (gene fragments) together, forming a strong stimulating effect on the immune system and can generate effective antibody vaccine, called appROACH vaccine. The appROACH vaccine is exciting in effect first. In addition to the 100% subjects who developed antibodies against the HIV virus, but also let the subjects single exposure to the AIDS virus (HIV) infection risk was reduced by 94%, and there are 66% people in the 6 exposure to HIV is still protected, not infected by HIV.

The vaccine was tested with "initial immunization booster immunization" strategy, that is, in the trial, subjects received a total of 4 vaccine injections, the first two vaccines were initial immunization, the latter two vaccines were booster immunization. After 48 weeks of injection, the subjects did not produce any side effects. Blood tests showed that all human bodies produced antibodies against HIV. The risk of HIV infection was reduced by 94% in assessing the actual protection of subjects.

The AIDS vaccine mosaic have a significant effect the main reason is that the vaccine designed according to the characteristics of HIV, the most important is the variety of antigen by HIV, which is selected from a plurality of different subtypes of HIV virus gene, the HIV antigen produced by viral vectors, the composition containing multiple HIV antigen vaccine.


Prev:NoneNext:None
News / Related news More
2017 - 10 - 19
Johnson announced in July 24th the world's first HIV vaccine in human clinical trials, this multicenter, randomized, placebo-controlled, double-blind phase 1/2a clinical trial recruited 393 healthy volunteers, volunteers from the United States, Rwanda, Uganda, South Africa and Thailand. The results showed that the volunteers of HIV vaccine was well tolerated, and produced antibody against HIV 100%...
Copyright © 2005 - 2017 Hangzhou Tacon Co.,LTD

犀牛云提供企业云服务
ADD:West business center,Gongshu District,Hangzhou City, China
TEL: 82 70 8259 7710
FAX: 82 31 811 7710

CODE:330520